Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision[i]

Actives substances(s): Magrolimab

Latest Decision number(s): 1) P/0263/2023

Corresponding PIP number(s): 1) EMEA-002819-PIP01-20-M01

If the PIP has been submitted as part of a marketing authorisation application in order to comply with the requirements of Article 7 of the Paediatric Regulation (as a condition of the validation of the respective application) and a marketing authorisation was granted based on this application, then there is a legal obligation to complete that PIP. The same applies if there has been a successful post-authorisation application, where the PIP was included in order to comply with the requirements of Article 8 of the Paediatric Regulation.

Please confirm if any of the above applies:

Yes ☐ No ☒

If yes, it means that based on the Marketing Authorisation obtained at the end of that initial procedure or the successful post-authorisation application, as applicable, you are obliged to complete that PIP. That obligation cannot be cancelled by a unilateral decision, including by withdrawing the MA. Such PIP must be completed, unless it is modified in agreement with the PDCO by removing all outstanding PIP measures or granting a full product-specific waiver instead (upon relevant circumstances in accordance with the Paediatric Regulation). Non-completion of a binding PIP establishes noncompliance with the requirements of the Paediatric Regulation, which the European Medicines Agency has an obligation to report to the European Commission.

Please note that development of the medicinal product above in the following **condition(s)/indication(s)**:

- Treatment of acute myeloid leukaemia
- Treatment of myelodysplastic syndromes, including juvenile myelomonocytic leukaemia

☒ has been discontinued

for the following reason(s): (tick all that apply)

☒ (possible) lack of efficacy in adults

☒ (possible) lack of efficacy in children

☐ (possible) unsatisfactory safety profile in adults

☐ (possible) unsatisfactory safety profile in children

☐ commercial reasons (please specify:)

☐ manufacturing / quality problems

☐ other regulatory action (please specify:)

☒ other reason (please specify: no further EU Marketing Authorizations for these indications will be pursued)

Please add a brief description (max 2000 characters) of the reason(s) for the discontinuation:

Gilead has decided to discontinue further development of magrolimab due to a lack of efficacy observed in the myelodysplastic syndrome (MDS) and acute myeloid leukaemia (AML) adult populations studied. Given this, we do not feel it is warranted to test magrolimab in pediatric patients with myelodysplastic syndrome (MDS), juvenile myelomonocytic leukaemia (JMML), or acute myeloid leukaemia {AML). We do not plan to seek marketing authorization for magrolimab in any indication.

Date:	09 January 2025
Contact for inquiries from interested parties:	Gilead Sciences International Ltd
Telephone:	+44 (0) 1223 897 300
Email:	regulatory.pip@gilead.com

[i] This form will be published to the corresponding decision available on the website of the European Medicines Agency.